Thanks to everyone who attended our Virtual Fall Conference. Special thanks to our presenters for an engaging and informative afternoon!
Agenda:
Agenda:
- 1:00-2:15 p.m. The Role of Genetic Testing in the Diagnosis and Prognosis of Melanoma
- Jean-Paul De la O, Medical Science Liaison, Myriad Genetics
- Kevin Epstein, Castle Biosciences
- Dr. Omar Rashid, Surgical Oncologist, Holy Cross Hospital, Ft. Lauderdale, FL
- 2:15-3:00 p.m. Sunscreens and the Sunscreen Innovation Act
- Maryellen Maguire-Eisen, RN; Children’s Melanoma Prevention Foundation
About our presenters:
Jean-Paul De la O is Medical Science Liaison at Myriad Genetics. Myriad is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Its myPath® Melanoma test is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling. It distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%.
Kevin Epstein is a Dermatology and Oncology Specialty Consultant at Castle Biosciences. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Its tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. The company believes that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information. Its DecisionDx family of non-invasive tests provides an assessment of a patient’s specific risk of metastasis or recurrence of their cancer, enabling more informed decisions about their treatment plans. Its test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a gene expression profile, or GEP, test that predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is a GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma who have one or more risk factors. DecisionDx®-UM is a GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. The company also has active development programs for tests in several other dermatologic cancers with high clinical need. The most advanced program is focused on patients with difficult-to-diagnose pigmented lesion.
Omar M. Rashid, MD, JD, FACS, FSSO, DABS is a board certified Complex General Surgical Oncologist in Ft Lauderdale, FL, who specializes in cutaneous malignancies such as Melanoma, Merkel cell carcinoma, advanced Squamous and Basal cell carcinoma, and Sarcoma. Dr. Rashid was born and raised in South Florida, completed undergraduate studies at Dartmouth College, a dual degree MD-JD program at Duke University Schools of Medicine and Law, General Surgery Residency training at the Virginia Commonwealth University Health System and Massey Comprehensive National Cancer Institute designated Cancer Center, and Complex General Surgical Oncology Fellowship training at the H. Lee Moffitt National Comprehensive Cancer Network & National Cancer Institute designated Cancer Center & Research Institute.
Dr. Rashid was one of the first 100 surgeons in North America to obtain board certification from the American Board of Surgery in Complex General Surgical Oncology, the new certification for cancer surgeons. He returned to South Florida where his family still lives because it has been his dream to return home to help elevate the level of cancer care in the community where he grew up and he is actively involved in research, medical undergraduate and graduate education, and community service. He has affiliations with Harvard Medical School's oldest and largest teaching hospital, the Massachusetts General Hospital, the University of Miami Miller School of Medicine, Nova Southeastern University School of Medicine, and Holy Cross Hospital.
His research bibliography includes over 80 published articles, abstracts and book chapters and he actively collaborates to increase access to national and international clinical trials for cancer patients locally. He has been recognized for his clinical work and research internationally, with multiple awards, presentations and collaborations with physicians and medical societies in the Caribbean, Central America, South America, and Europe. He is an active member of the American Cancer Society Broward County and South East Florida Area volunteer boards and he has a passion for improving outcomes in cancer care. Dr. Rashid has no financial conflicts of interest to disclose.
Maryellen Maguire-Eisen RN, MSN is founder and chief executive officer of the Children’s Melanoma Prevention Foundation, a non-profit educational foundation that seeks to teach children and nurses about sun protection and skin cancer prevention. Prior to assuming that role, she was a nurse practitioner at South Shore Skin Center, Plymouth, Massachusetts, where her responsibilities included management of general dermatologic problems with a sub-specialization in skin oncology, which included diagnosis, treatment, and monitoring of side effects and disease states. She coordinated the mole mapping program and developed collaborative practice protocols and educational tools. She also provided community outreach education in local schools and taught skin cancer education to nurses locally and nationally.
Jean-Paul De la O is Medical Science Liaison at Myriad Genetics. Myriad is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Its myPath® Melanoma test is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling. It distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%.
Kevin Epstein is a Dermatology and Oncology Specialty Consultant at Castle Biosciences. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Its tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. The company believes that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information. Its DecisionDx family of non-invasive tests provides an assessment of a patient’s specific risk of metastasis or recurrence of their cancer, enabling more informed decisions about their treatment plans. Its test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a gene expression profile, or GEP, test that predicts a patient’s risk of metastasis or recurrence as well as sentinel lymph node positivity. DecisionDx®-SCC is a GEP test that predicts the risk of metastasis for patients with cutaneous squamous cell carcinoma who have one or more risk factors. DecisionDx®-UM is a GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. The company also has active development programs for tests in several other dermatologic cancers with high clinical need. The most advanced program is focused on patients with difficult-to-diagnose pigmented lesion.
Omar M. Rashid, MD, JD, FACS, FSSO, DABS is a board certified Complex General Surgical Oncologist in Ft Lauderdale, FL, who specializes in cutaneous malignancies such as Melanoma, Merkel cell carcinoma, advanced Squamous and Basal cell carcinoma, and Sarcoma. Dr. Rashid was born and raised in South Florida, completed undergraduate studies at Dartmouth College, a dual degree MD-JD program at Duke University Schools of Medicine and Law, General Surgery Residency training at the Virginia Commonwealth University Health System and Massey Comprehensive National Cancer Institute designated Cancer Center, and Complex General Surgical Oncology Fellowship training at the H. Lee Moffitt National Comprehensive Cancer Network & National Cancer Institute designated Cancer Center & Research Institute.
Dr. Rashid was one of the first 100 surgeons in North America to obtain board certification from the American Board of Surgery in Complex General Surgical Oncology, the new certification for cancer surgeons. He returned to South Florida where his family still lives because it has been his dream to return home to help elevate the level of cancer care in the community where he grew up and he is actively involved in research, medical undergraduate and graduate education, and community service. He has affiliations with Harvard Medical School's oldest and largest teaching hospital, the Massachusetts General Hospital, the University of Miami Miller School of Medicine, Nova Southeastern University School of Medicine, and Holy Cross Hospital.
His research bibliography includes over 80 published articles, abstracts and book chapters and he actively collaborates to increase access to national and international clinical trials for cancer patients locally. He has been recognized for his clinical work and research internationally, with multiple awards, presentations and collaborations with physicians and medical societies in the Caribbean, Central America, South America, and Europe. He is an active member of the American Cancer Society Broward County and South East Florida Area volunteer boards and he has a passion for improving outcomes in cancer care. Dr. Rashid has no financial conflicts of interest to disclose.
Maryellen Maguire-Eisen RN, MSN is founder and chief executive officer of the Children’s Melanoma Prevention Foundation, a non-profit educational foundation that seeks to teach children and nurses about sun protection and skin cancer prevention. Prior to assuming that role, she was a nurse practitioner at South Shore Skin Center, Plymouth, Massachusetts, where her responsibilities included management of general dermatologic problems with a sub-specialization in skin oncology, which included diagnosis, treatment, and monitoring of side effects and disease states. She coordinated the mole mapping program and developed collaborative practice protocols and educational tools. She also provided community outreach education in local schools and taught skin cancer education to nurses locally and nationally.